Get the Stockscreener App
84.02
1.31%
1.09
Bio Rad Laboratories Inc stock is traded at $84.02, with a volume of 2.06M.
It is up +1.31% in the last 24 hours and up +0.00% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$82.93
Open:
$83.46
24h Volume:
2.06M
Relative Volume:
10.26
Market Cap:
$16.46B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-22.43
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
+3.24%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$82.74
$85.30
1-Week Range:
$80.70
$85.30
52-Week Range:
$78.98
$85.30
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
84.02 | 16.46B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BBIO) Latest News
Bio-Rad Laboratories (BIO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio-Rad Laboratories (BIO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100 - GuruFocus
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - BioSpace
Press Release: Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Bio-Rad will discuss Q2 results at 5 p.m. ET on Aug. 4 - Stock Titan
Bio-Rad Laboratories stock holds on to year-end earnings context - AD HOC NEWS
Bio-Rad Laboratories (BIO) Experiences Minor Decline Amid Compet - GuruFocus
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Diagnostic Reagent Market is Going to Boom: New Report Reveals - openPR.com
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - Yahoo Finance
In Fight With GC, Bio-Rad Adds Quinn Emanuel to Legal Team - Law.com
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad Laboratories (BIO) Surges 4.4% as Bullish Momentum Builds From Key Support LevelOBV Divergence - dars.gov.et
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Medical Device Terrain with a 3.22% Upside - DirectorsTalk Interviews
Elliott Targets Bio-Rad After 70% Stock Collapse - Yahoo Finance
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus - Sahm
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday - Benzinga
Activist Elliott Investment Management Has Built A Sizable Stake In Bio-Rad Laboratories- WSJ - TradingView
Bio-Rad Expands Antibody Labeling Kits for Flow Cytometry and Western Blot - Clinical Lab Products
Morgan Stanley files Rule 144 notice to sell 550 BIO shares (NYSE: BIO) - Stock Titan
Bio‑Rad expands TrailBlazer kits for antibody conjugation to StarBright dyes - Select Science
Bio-Rad to Participate in Upcoming Investor ConferencesMay 8, 2026 - BioSpace
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out - Yahoo Finance
Bio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab Manager
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Bio-Rad drops 10.2% as guidance cut and Sartorius valuation hit overshadow Q1 results - Quiver Quantitative
Bio-Rad introduces the PTC Harmony 96 and PTC Harmony Deepwell thermal cyclers - Select Science
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers - News-Medical
Bio Rad Laboratories Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):